What should I know first?

The term commonly refers to insufficient benefit from at least two adequately tried antidepressants. Clinicians review the dose, duration, adherence and diagnosis before concluding that a treatment has failed. Definitions and eligibility criteria differ across research, medicine licences and services.

Important Distinctions

Treatment resistance does not mean that recovery is impossible or that a person has failed. Options may include psychological treatment, changes to medicines, augmentation and brain stimulation. Eligibility for ketamine or esketamine requires a separate clinical assessment and country-specific information.

Sources and References

  1. Depression: treatment and brain stimulation options
  2. Spravato: current US prescribing information (revised March 2026)
  3. Spravato 28 mg nasal spray: UK Summary of Product Characteristics

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top